DK2171060T3 - Superagonistisk anti-CD28-antistof - Google Patents

Superagonistisk anti-CD28-antistof

Info

Publication number
DK2171060T3
DK2171060T3 DK05802650.1T DK05802650T DK2171060T3 DK 2171060 T3 DK2171060 T3 DK 2171060T3 DK 05802650 T DK05802650 T DK 05802650T DK 2171060 T3 DK2171060 T3 DK 2171060T3
Authority
DK
Denmark
Prior art keywords
antibody
superagonist anti
superagonist
Prior art date
Application number
DK05802650.1T
Other languages
English (en)
Inventor
Thomas Hanke
Martin Trischler
Christine Guntermann
Original Assignee
Theramab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theramab Llc filed Critical Theramab Llc
Application granted granted Critical
Publication of DK2171060T3 publication Critical patent/DK2171060T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK05802650.1T 2004-11-11 2005-11-10 Superagonistisk anti-CD28-antistof DK2171060T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004055622 2004-11-11
EP05010264 2005-05-11
PCT/EP2005/012050 WO2006050949A2 (de) 2004-11-11 2005-11-10 Superagonistische anti-cd28 antikörper

Publications (1)

Publication Number Publication Date
DK2171060T3 true DK2171060T3 (da) 2013-12-16

Family

ID=36087857

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05802650.1T DK2171060T3 (da) 2004-11-11 2005-11-10 Superagonistisk anti-CD28-antistof

Country Status (5)

Country Link
EP (2) EP2171060B1 (da)
DK (1) DK2171060T3 (da)
ES (1) ES2437571T3 (da)
PT (1) PT2171060E (da)
WO (1) WO2006050949A2 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009112502A1 (en) 2008-03-13 2009-09-17 Biotest Ag Agent for treating disease
BRPI0909048A2 (pt) 2008-03-13 2015-11-24 Biotest Ag composição farmacêutica, e, método de tratamento de uma doença autoimune
HUE028962T2 (en) 2008-03-13 2017-01-30 Biotest Ag Active ingredient for treating disease
US20110082091A1 (en) 2009-09-28 2011-04-07 Theramab Gmbh Method for Preclinical Testing of Immunomodulatory Drugs
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
AU2019410073B2 (en) 2018-12-21 2024-08-01 F. Hoffmann-La Roche Ag Tumor-targeted agonistic CD28 antigen binding molecules
AR117728A1 (es) 2018-12-21 2021-08-25 Hoffmann La Roche Moléculas superagonistas de unión al antígeno cd28 con diana tumoral
AU2021295549A1 (en) 2020-06-23 2022-11-24 F. Hoffmann-La Roche Ag Agonistic CD28 antigen binding molecules targeting Her2
EP4172203A1 (en) 2020-06-25 2023-05-03 F. Hoffmann-La Roche AG Anti-cd3/anti-cd28 bispecific antigen binding molecules
WO2022214652A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
WO2023170474A1 (en) 2022-03-07 2023-09-14 Novimmune Sa Cd28 bispecific antibodies for targeted t cell activation
WO2023193239A1 (en) * 2022-04-08 2023-10-12 Peter Peizhi Luo Anti-cd28 antibodies and methods of use thereof
US20240254234A1 (en) 2022-10-21 2024-08-01 Novimmune Sa PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION
WO2024094741A1 (en) 2022-11-03 2024-05-10 F. Hoffmann-La Roche Ag Combination therapy with anti-cd19/anti-cd28 bispecific antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19722888A1 (de) * 1997-05-28 1998-12-03 Thomas Prof Dr Huenig Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten
DE10160516A1 (de) 2001-12-04 2003-06-12 Tegenero Gmbh Peptid oder Protein enthaltend ein C'-D Loop der CD28 Rezeptorfamilie
WO2003048194A2 (de) * 2001-12-04 2003-06-12 Tegenero Ag Peptid oder protein enthaltend ein c'-d loop der cd28 rezeptorfamilie
DE10212108A1 (de) 2002-03-13 2003-10-02 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
DE10230223A1 (de) 2002-07-04 2004-01-22 Tegenero Ag Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
DE10352900A1 (de) * 2003-11-11 2005-06-16 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL

Also Published As

Publication number Publication date
EP2497829A1 (de) 2012-09-12
PT2171060E (pt) 2013-11-18
EP2171060B1 (de) 2013-10-02
WO2006050949A3 (de) 2006-07-13
EP2171060A2 (de) 2010-04-07
ES2437571T3 (es) 2014-01-13
WO2006050949A2 (de) 2006-05-18

Similar Documents

Publication Publication Date Title
DK2171060T3 (da) Superagonistisk anti-CD28-antistof
LTPA2018515I1 (lt) Antagonistiniai IL-17 antikūnai
LTC1963368I2 (lt) Anti-il-17 antikūnai
NO20071430L (no) Anti-OX4OL antistoffer
DK1737891T3 (da) Anti-p-selectin-antistoffer
DE602006017373D1 (de) Madcam-antikörper
DK1964852T3 (da) Anti-ilt7-antistof
NO20076607L (no) TWEAK - bindende antistoff
NL1027975A1 (nl) Antilichamen tegen MAdCAM.
DK1599504T3 (da) Modificeret antistof
DK3332808T3 (da) Humaniserede L243-antistoffer
DK1853310T3 (da) Anti-Abeta-antistofpræparat
NO20071069L (no) Anti-CD154-antistoff
DK1771482T3 (da) HER2-antistofsammensætning
ATE414693T1 (de) Neuartige cis-imidazoline
CY2013046I2 (el) Καινοτομος χρηση των αντισωματων αντι il-1bhta
DE502005008168D1 (de) Pipette
BRPI0509495A2 (pt) anticorpo humanizado
DK1812475T3 (da) Immunglobulinfraktioner
FI20041538A0 (fi) Goniometri
DE602005005256D1 (de) Siebvorrichtung
DE502005002052D1 (de) Transportvorrichtung
IS8562A (is) Ónæmisglóbúlín
FI6402U1 (fi) Julistelista
UA10485S (uk) Павільйон